![]() |
|
|
Vol. 280, Issue 3, 1489-1498, 1997
From the Departments of Medicine and Pharmacology (J.A.C., N.B.,
R.-d.Z., and L.L.S.),
Obstetrics-Gynecology (J.C.) and
Urology
(L.G.G.), Jefferson Medical College, Philadelphia, Pennsylvania
Human exposure to botulinum toxin typically occurs in two settings: 1)
as an etiologic agent in the disease botulism and 2) as a therapeutic
agent for the treatment of dystonia. Epidemiologic studies on botulism
suggest that the human nervous system is susceptible to five toxin
serotypes (A, B, E, F and G) and resistant to two (C and D). In the
past, these epidemiologic findings have been used as the basis for
selecting serotypes that should be tested as therapeutic agents for
dystonia. Epidemiologic data have been utilized because there are no
studies of botulinum neurotoxin action on isolated human nerves. In the
present study, electrophysiologic techniques were used to monitor toxin
effects on neuromuscular transmission in surgically excised human
pyramidalis muscles, ligand binding studies were done to detect and
characterize toxin receptors in human nerve membrane preparations, and
molecular biologic techniques were used to isolate and sequence a human gene that encodes a substrate for botulinum neurotoxin. The results demonstrated that stable resting membrane potentials (
61.5 mV; S.E.M. ± 0.7) were maintained in individual fibers of pyramidalis muscle for
up to 6 hr at 33°C. The rate of spontaneous miniature endplate
potentials was low in physiologic solution (0.14 sec
1)
but increased in response to elevations in extracellular potassium concentration. In keeping with epidemiologic findings, botulinum toxin
type A (10
8 M) paralyzed transmission in human
preparations (ca. 90 min). In contrast to epidemiologic
findings, serotype C (10
8 M) also paralyzed human tissues
(ca. 65 min). Iodinated botulinum toxin displayed
high-affinity binding to receptors in human nerve membrane preparations
(serotype A high-affinity site: Kd = 0.3 nM,
Bmax = 0.78 pmol/mg protein; serotype C
high-affinity site: Kd = 1.96 nM,
Bmax = 8.9 pmol/mg protein). In addition, the
human nervous system was found to encode polypeptides that are
substrates for botulinum neurotoxin types A (synaptosomal-associated protein of Mr 25,000) and C (syntaxin 1A). These data have
important implications bearing on: 1) the development and
administration of vaccines against botulism and 2) the testing of toxin
serotypes for the treatment of dystonia.
This article has been cited by other articles:
![]() |
Y. Jin, Y. Takegahara, Y. Sugawara, T. Matsumura, and Y. Fujinaga Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins - differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C Microbiology, January 1, 2009; 155(1): 35 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tsukamoto, T. Kohda, M. Mukamoto, K. Takeuchi, H. Ihara, M. Saito, and S. Kozaki Binding of Clostridium botulinum Type C and D Neurotoxins to Ganglioside and Phospholipid: NOVEL INSIGHTS INTO THE RECEPTOR FOR CLOSTRIDIAL NEUROTOXINS J. Biol. Chem., October 21, 2005; 280(42): 35164 - 35171. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Maksymowych and L. L. Simpson Structural Features of the Botulinum Neurotoxin Molecule That Govern Binding and Transcytosis across Polarized Human Intestinal Epithelial Cells J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 633 - 641. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kalandakanond and J. A. Coffield Cleavage of Intracellular Substrates of Botulinum Toxins A, C, and D in a Mammalian Target Tissue J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 749 - 755. [Abstract] [Full Text] |
||||
![]() |
J. A. Coffield, N. M. Bakry, A. B. Maksymowych, and L. L. Simpson Characterization of a Vertebrate Neuromuscular Junction That Demonstrates Selective Resistance to Botulinum Toxin J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1509 - 1516. [Abstract] [Full Text] |
||||
![]() |
A. B. Maksymowych and L. L. Simpson Binding and Transcytosis of Botulinum Neurotoxin by Polarized Human Colon Carcinoma Cells J. Biol. Chem., August 21, 1998; 273(34): 21950 - 21957. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Simpson, A. B. Maksymowych, and S. Hao The Role of Zinc Binding in the Biological Activity of Botulinum Toxin J. Biol. Chem., July 13, 2001; 276(29): 27034 - 27041. [Abstract] [Full Text] [PDF] |
||||